PI3K Inhibitors in Cardiovascular Disease
- 17 January 2011
- journal article
- review article
- Published by Wiley in Cardiovascular Therapeutics
- Vol. 29 (1), 29-36
- https://doi.org/10.1111/j.1755-5922.2010.00206.x
Abstract
Cardiovascular diseases, including atherosclerotic disease and its thrombotic complications are one main cause of hospitalization and mortality in the world. The family of phosphoinositide 3-kinases (PI3Ks) play an important role in the pathogenesis of cardiovascular diseases by regulating essential cellular functions, such as cell migration, translational responses, and cell survival, and thereby, modulating several essential biologic processes, such as metabolism, vascular homeostasis and thrombogenicity. PI3Ks can be divided into three classes, of which the class I-group is the best characterized. This group consists of four isoforms, named PI3Kα, β, δ, and γ. Each isoform has distinct functions under normal as well as pathophysiologic conditions. The development of several pharmacologic isoform-selective, isoform-preferring, and pan-PI3K inhibitors enlarged and potentiated the knowledge about the effect of the different PI3K isoforms on specific biologic processes as well as their role under pathophysiologic conditions. Moreover, this offered the possibility for novel therapeutic strategies targeting PI3K isoforms in cardiovascular diseases. Therefore, this review will focus on the pathophysiologic role of class I PI3Ks in cardiovascular diseases as well as on the therapeutic potential of pharmacological PI3K inhibitors for the treatment of this scourge of humanity.Keywords
This publication has 77 references indexed in Scilit:
- Role of Phosphoinositide 3-Kinase β in Glycoprotein VI-mediated Akt Activation in PlateletsOnline Journal of Public Health Informatics, 2009
- Non-redundant Roles of Phosphoinositide 3-Kinase Isoforms α and β in Glycoprotein VI-induced Platelet Signaling and Thrombus FormationOnline Journal of Public Health Informatics, 2009
- Toll‐like receptor agonists induce inflammation and cell death in a model of head and neck squamous cell carcinomasImmunology, 2009
- Heart Disease and Stroke Statistics—2009 UpdateCirculation, 2009
- Chapter 2 PI3K/PTEN Signaling in Angiogenesis and TumorigenesisPublished by Elsevier BV ,2009
- Phosphoinositide 3-Kinase γ Gene Knockout Impairs Postischemic Neovascularization and Endothelial Progenitor Cell FunctionsArteriosclerosis, Thrombosis, and Vascular Biology, 2008
- Deletion of the phosphoinositide 3-kinase p110γ gene attenuates murine atherosclerosisProceedings of the National Academy of Sciences of the United States of America, 2007
- Exploring the specificity of the PI3K family inhibitor LY294002Biochemical Journal, 2007
- Phosphoinositide 3-kinase γ/δ inhibition limits infarct size after myocardial ischemia/reperfusion injuryProceedings of the National Academy of Sciences of the United States of America, 2006
- A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin SignalingCell, 2006